Jul 20, 2020
Steven M. Fruchtman, M.D.,
President and Chief Executive Officer, Onconova Therapeutics
discusses Rigosertib, a drug that has the potential to downregulate
the RAS pathway, the most commonly mutated gene in cancer.
Rigosertib is a proprietary phase 3 small molecule, currently being
evaluated in second-line treatment of patients with higher-risk
myelodysplastic syndrome (MDS) and refractory higher-risk MDS
patients. Also known as pre-leukemia, MDS is a cancer of the
bone marrow stem cell and the mission of Onconova is to prolong the
lives of those suffering from this disease.
#cancer #oncology #RAS #MDS #PreLeukemia #Leukemia $ONTX